SOBI increases revenues by 25%, boosted by a doubling of Orfadin sales

Biotech firm Swedish Orphan Biovitrum (SOBI: SS), has announced total revenues of 665.9 million Swedish kronor ($99.8 million) for the third quarter of 2014, an increase of 25.2% on figures from the same period last year.

Orfadin doubles its sales

Product revenues stood at 532.3 million kronor, up from 393.5 million kronor in the same period last year, and SOBI reports revenues for Key Therapeutic Areas as 372 million kronor – an increase of 51%. Orfadin (nitisinone) had a 100% boost in sales, from 81.9 million kronor in the third quarter of 2013 to 163.5 million kronor this quarter. It cites the beginning of direct sales in North America in the second quarter as the reason for such a big leap in revenue.